Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03238781 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 343
- Enrollment target
NCT03238781 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 343 participants.
The verdict
NCT03238781, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 343 participants
- Enrollment target
Study Summary
To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
Interventions
- DRUG Placebo
- DRUG AMG 301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03238781
The ClinicalTrials.gov registry entry for NCT03238781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03238781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03238781 about?
NCT03238781 is a clinical study titled "Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention". To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
What is the current status of trial NCT03238781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 343 participants. The study started on 2017-09-06. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT03238781?
The interventions under investigation include: Placebo (DRUG), AMG 301 (DRUG).
Who is sponsoring clinical trial NCT03238781?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.